Ovid Therapeutics Inc.OVID

Market cap

$105.24M

P/E ratio

	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Revenue	-	-	-	-	-	223	223	1
Research and development	50	34	42	63	47	25	29	37
General and administrative	15	19	19	31	37	32	31	26
Total operating expenses	65	53	61	94	84	57	60	62
Loss from operations	-65,007,563	-52,931,683	-61,409,467	-81,430,977	124	-55,548,161	-59,281,464	-62
Other income (expense), net	-	-	-	-	-	1	7	35
Loss before provision for income taxes	-	-	-	-	124	-54,169,029	-52,338,959	-26
Provision for income taxes	-	-	-	-	1	-	-	-
Net loss	-64,806,054	-51,979,610	-60,461,243	-81,035,576	123	-54,169,029	-52,338,959	-26
Series A Preferred Stock	-	-	-	-	-	-	-	-366.33
Common Stock	-	-	-	-	-	-	-	-0.37
Earnings Per Share, Basic	-	-	-	-	1.78	-0.77	-0.74	-
Series A Preferred Stock	-	-	-	-	-	-	-	-366.33
Common Stock	-	-	-	-	-	-	-	-0.37
Earnings Per Share, Diluted	-	-	-	-	1.76	-0.77	-0.74	-